Evidence map›Paper›PMID 25859270›Full record

ArticleJournal of biomedical research2015

Evaluation of metal nanoparticles for drug delivery systems.

Oluyomi S Adeyemi, Faoziyat A Sulaiman

Open access · greenAbstract read
In one paragraph

Article in Journal of biomedical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Biosynthesis of Selenium Nanoparticles (viaMolecules (Basel, Switzerland) · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Silver Nanoparticles Biosynthesized WithFrontiers in veterinary science · 2020
    Article
  16. Biogenic Silver Nanoparticles Can ControlFrontiers in microbiology · 2020
    Article
  17. Anti-Bioscience reports · 2019
    Article
  18. Article
  19. Surface modification minimizes the toxicity of silver nanoparticles: an in vitro and in vivo study.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Oluyomi S AdeyemiDepartment of Biological Sciences, Landmark University, Omu-Aran, Kwara State, Nigeria;
Faoziyat A SulaimanDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.
Landmark University · NGUniversity of Ilorin · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diminazene aceturate is a trypanocide with unwanted toxicity and limited efficacy. It was reasoned that conjugating diminazene aceturate to functionalized nanoparticle would lower untoward toxicity while improving selectivity and therapeutic efficacy. Silver and gold nanoparticles were evaluated for their capacities to serve as carriers for diminazene aceturate. The silver and gold nanoparticles were synthesized, functionalized and coupled to diminazene aceturate following established protocols. The nanoparticle conjugates were characterized. The free diminazene aceturate and drug conjugated nanoparticles were subsequently evaluated for cytotoxicity in vitro. The characterizations by transmission electron microscopy or UV/Vis spectroscopy revealed that conjugation of diminazene aceturate to silver or gold nanoparticles was successful. Evaluation for cytotoxic actions in vitro demonstrated no significance difference between free diminazene aceturate and the conjugates. Our data suggest that surface modified metal nanoparticles could be optimized for drug delivery systems.

Indexed as

drugsnanoparticlestargetingtoxicitytrypanocides

Identifiers

PMID25859270
PMCPMC4389115
OpenAlexW2269896229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.